QuidelOrtho Q3 2026 slides: profit beat masks revenue challenges
QuidelOrtho (QDEL) reported Q3 2026 earnings of $0.31 per share, beating estimates, but revenue of $618.9M missed forecasts, causing a 6.62% after-hours drop. Revenue declined 12% YoY due to China's IVD pricing guidelines, with North America down 13.3% and China down 45.5%. Management narrowed full-year guidance, citing continued China pressure and cautious respiratory demand outlook. The company announced a restructuring plan to save $80M annually from 2027.
How this was made
The 30-second read
Why it matters
Guidance reduction and China revenue decline drive immediate downside risk; restructuring may improve margins in 2027.
Market read
First‑report earnings and guidance update for QDEL, material for traders with exposure to healthcare diagnostics.
What to watch
Strong recurring revenue (96%) and growth in labs/immunohematology outside China may cushion long‑term performance.
Background
QuidelOrtho is a U.S. diagnostics company with exposure to China IVD pricing reforms.
Ticker impact
QDEL reported Q3 2026 earnings with profit beat but revenue miss and narrowed full-year guidance, causing a 6.6% after‑hours price drop.
downward pressure as investors price in weaker revenue and lower guidance
The earnings release showed a 12% YoY revenue decline, a 45% China drop, and a narrowed 2026 revenue range, which historically triggers sell‑offs.
Market effects
Diagnostic testing sector may see broader pressure as China pricing guidelines impact peers.
North American diagnostic stocks could face short‑term weakness.
Limited to healthcare investors; no broad market effect.
Counterpoint
The restructuring plan and $80M annual savings target could support a rebound later in 2027.
Key entities
- ExecutiveBrian Blaser
Chief Executive Officer of QuidelOrtho



